View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 14, 2020updated 22 Nov 2021 10:49am

Coherus signs in-licensing agreement for Avastin biosimilar

Coherus BioSciences has signed an in-licensing agreement to acquire commercial rights of Innovent Biologics’ biosimilar candidate to Avastin (bevacizumab) (IBI305) in the US and Canada.

Coherus BioSciences has signed an in-licensing agreement to acquire commercial rights of Innovent Biologics’ biosimilar candidate to Avastin (bevacizumab) (IBI305) in the US and Canada.

The agreement aligns with Coherus’ strategy to expand its oncology franchise.

Under the agreement, Coherus will pay Innovent up to $45m as upfront and milestones payments for IBI305. Additionally, Innovent will also receive a double-digit per cent of royalty payments from future commercial sales of IBI305.

IBI305 is a recombinant humanised anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody for the treatment of non-small cell lung cancer (NSCLC), colorectal cancer and other malignant tumours.

It completed an extensive Phase III safety and efficacy study in China, securing priority review status in the country.

Coherus now plans to file a Biologics License Application (BLA) in the US in late this year or early 2021. Once approved, the company will launch IBI305 in the market.

Innovent founder, chairman and CEO Michael Yu said: “The clinical efficacy and safety results of IBI305 compared with bevacizumab in advanced, first-line, non-squamous NSCLC patients were presented at the 55th Annual Meeting of the ASCO in 2019.

“With the encouraging results, IBI305 is expected to be a high-quality and effective therapy for patients with solid tumours.”

The agreement also provides Coherus with an option to licence Innovent’s biosimilar to Rituxan (rituximab) (IBI301) in the US and Canada.

In June, the National Medical Products Administration (NMPA) in China granted IBI301 priority review status.

The financial terms associated with the Innovent’s Rituxan biosimilar will be the same when exercised.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology